Home Cart 0 Sign in  

[ CAS No. 2389-60-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 2389-60-8
Chemical Structure| 2389-60-8
Structure of 2389-60-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 2389-60-8 ]

Related Doc. of [ 2389-60-8 ]

Alternatived Products of [ 2389-60-8 ]

Product Details of [ 2389-60-8 ]

CAS No. :2389-60-8 MDL No. :MFCD00062271
Formula : C19H28N2O6 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 380.44 Pubchem ID :-
Synonyms :

Calculated chemistry of [ 2389-60-8 ]

Physicochemical Properties

Num. heavy atoms : 27
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.53
Num. rotatable bonds : 14
Num. H-bond acceptors : 6.0
Num. H-bond donors : 3.0
Molar Refractivity : 99.85
TPSA : 113.96 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.6 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.2
Log Po/w (XLOGP3) : 2.84
Log Po/w (WLOGP) : 2.91
Log Po/w (MLOGP) : 1.92
Log Po/w (SILICOS-IT) : 2.07
Consensus Log Po/w : 2.59

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 1.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.23
Solubility : 0.225 mg/ml ; 0.000591 mol/l
Class : Soluble
Log S (Ali) : -4.89
Solubility : 0.00488 mg/ml ; 0.0000128 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.47
Solubility : 0.0128 mg/ml ; 0.0000336 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.44

Safety of [ 2389-60-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 2389-60-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 2389-60-8 ]
  • Downstream synthetic route of [ 2389-60-8 ]

[ 2389-60-8 ] Synthesis Path-Upstream   1~20

  • 1
  • [ 2389-60-8 ]
  • [ 2212-75-1 ]
Reference: [1] Journal of the American Chemical Society, 1982, vol. 104, # 16, p. 4446 - 4450
[2] Patent: EP1426366, 2004, A1, . Location in patent: Page 28-29
  • 2
  • [ 24424-99-5 ]
  • [ 2212-75-1 ]
  • [ 2389-60-8 ]
YieldReaction ConditionsOperation in experiment
100% With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃; N-α-Cbz-(S)-Lysine (5g, 17.85mmol) was dissolved in a mixture of THF (5OmL) and water (5OmL). To this sodium bicarbonate (3g, 35.5mmol, 2eq) and a solution OfBoC2O (9g, 41mmol, 2.3eq) in THF (5OmL). After stirring at room temperature overnight, the THF was removed under reduced pressure and the resulting aqueous solution was neutralized with 2N HCl. This was extracted with ethyl acetate and the combined organic layers were washed with brine. The organic layer was dried with sodium sulfate and concentrated to a clear oil. Removal of excess BoC2O by Kugelrhor distillation resulted in a thick clear oil weighing 6.Sg, 100percent. 1HNMR (CDCl3) δ 11.6 (s, IH), 7.32 (s, 5H)5 6.36 (s, IH)5 5.75 (d, IH5 J=8)5 5.09 (s, 2H)5 4.37(m5 IH), 3.06 (m, 2H), 1.78 (m, 2H)5 1.53 (s, 4H)5 1.42 (s, 9H). 13C NMR (CDCl3) δ 174.8, 155.4, 135.4, 127.6, 127.3, 127.2, 78.6, 66.1, 52.9, 39.2, 31.0, 28.6, 27.5, 26.6, 21.4
100%
Stage #1: With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃;
Stage #2: With hydrogenchloride In water
a. Synthesis of Compound 1 (NBoc-Cbz Lysine) N-?-Cbz-(S)-Lysine (5 g, 17.85 mmol) was dissolved in a mixture of THF (50 mL) and water (50 mL). To this sodium bicarbonate (3 g, 35.5 mmol, 2 eq) and a solution of Boc2O (9 g, 41 mmol, 2.3 eq) in THF (50 mL). After stirring at room temperature overnight, the THF was removed under reduced pressure and the resulting aqueous solution was neutralized with 2N HCl. This was extracted with ethyl acetate and the combined organic layers were washed with brine. The organic layer was dried with sodium sulfate and concentrated to a clear oil. Removal of excess Boc2O by Kugelrhor distillation resulted in a thick clear oil weighing 6.8 g, 100percent. 1H NMR (CDCl3) ? 11.6 (s, 1H), 7.32 (s, 5H), 6.36 (s, 1H), 5.75 (d, 1H, J=8), 5.09 (s, 2H), 4.37 (m, 1H), 3.06 (m, 2H), 1.78 (m, 2H), 1.53 (s, 4H), 1.42 (s, 9H). 13C NMR (CDCl3) ? 174.8, 155.4, 135.4, 127.6, 127.3, 127.2, 78.6, 66.1, 52.9, 39.2, 31.0, 28.6, 27.5, 26.6, 21.4
100%
Stage #1: With sodium hydrogencarbonate In tetrahydrofuran at 20℃;
Example 6. Synthesis of Lysine Teroxazole Intermediate 309; A lysine teroxazole intermediate that can be used to prepare compounds of the invention can be prepared as follows <n="50"/>a. Synthesis of Compound 301 (NBoc-Cbz Lysine)N-α-Cbz-(S)-Lysine (5g, 17.85mmol) was dissolved in a mixture of THF (5OmL) and water (5OmL). To this sodium bicarbonate (3g, 35.5mmol, 2eq) and a solution of BoC2O (9g, 41mmol, 2.3eq) in THF (5OmL). After stirring at room temperature overnight, the THF was removed under reduced pressure and the resulting aqueous solution was neutralized with 2N HCl. This was extracted with ethyl acetate and the combined organic layers were washed with brine. The organic layer was dried with sodium sulfate and concentrated to a clear oil. Removal of excess BoC2O by Kugelrhor distillation resulted in a thick clear oil weighing 6.8g, 100percent. H NMR (CDCl3) δ 11.6 (s, IH), 7.32 (s, 5H), 6.36 (s, IH), 5.75 (d, IH, J=8), 5.09 (s, 2H), 4.37(m, IH), 3.06 (m, 2H), 1.78 (m, 2H), 1.53 (s, 4H), 1.42 (s, 9H). 13C NMR (CDCl3) δ 174.8, 155.4, 135.4, 127.6, 127.3, 127.2, 78.6, 66.1, 52.9, 39.2, 31.0, 28.6, 27.5, 26.6, 21.4.
Reference: [1] Patent: WO2007/127173, 2007, A2, . Location in patent: Page/Page column 34
[2] Patent: US2009/156627, 2009, A1, . Location in patent: Page/Page column 25
[3] Patent: WO2009/18549, 2009, A1, . Location in patent: Page/Page column 49
[4] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 2, p. 305 - 308
[5] Journal of the Chemical Society - Perkin Transactions 1, 1998, # 2, p. 359 - 365
[6] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 10, p. 3150 - 3154
  • 3
  • [ 501-53-1 ]
  • [ 130384-98-4 ]
  • [ 2389-60-8 ]
Reference: [1] Patent: WO2008/14811, 2008, A1, . Location in patent: Page/Page column 17-18
  • 4
  • [ 2418-95-3 ]
  • [ 501-53-1 ]
  • [ 2389-60-8 ]
Reference: [1] Journal of the American Chemical Society, 1982, vol. 104, # 16, p. 4446 - 4450
[2] Bulletin of the Chemical Society of Japan, 1964, vol. 37, p. 1471 - 1477
[3] Patent: WO2018/51197, 2018, A1, . Location in patent: Paragraph 0088; 0174
  • 5
  • [ 1070-19-5 ]
  • [ 2212-75-1 ]
  • [ 2389-60-8 ]
Reference: [1] Journal of the American Chemical Society, 1965, vol. 87, p. 99 - 104
[2] Journal of the American Chemical Society, 1968, vol. 90, # 20, p. 5598 - 5603
[3] Journal of Organic Chemistry, 1971, vol. 36, p. 3022 - 3026
[4] Chemische Berichte, 1964, vol. 97, p. 3305 - 3311
[5] Justus Liebigs Annalen der Chemie, 1964, vol. 674, p. 218 - 225
  • 6
  • [ 2212-75-1 ]
  • [ 6627-89-0 ]
  • [ 2389-60-8 ]
Reference: [1] Synthetic Communications, 1981, vol. 11, # 4, p. 303 - 314
  • 7
  • [ 657-27-2 ]
  • [ 2389-60-8 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1999, vol. 47, # 10, p. 1489 - 1490
[2] Synthetic Communications, 1981, vol. 11, # 4, p. 303 - 314
  • 8
  • [ 14511-39-8 ]
  • [ 2389-60-8 ]
Reference: [1] Synthetic Communications, 1981, vol. 11, # 4, p. 303 - 314
[2] Chemische Berichte, 1964, vol. 97, p. 3305 - 3311
  • 9
  • [ 24424-99-5 ]
  • [ 2389-60-8 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1999, vol. 47, # 10, p. 1489 - 1490
  • 10
  • [ 501-53-1 ]
  • [ 2389-60-8 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1999, vol. 47, # 10, p. 1489 - 1490
  • 11
  • [ 13139-17-8 ]
  • [ 2418-95-3 ]
  • [ 2389-60-8 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1999, vol. 47, # 10, p. 1489 - 1490
  • 12
  • [ 2212-76-2 ]
  • [ 2389-60-8 ]
Reference: [1] Soft Matter, 2014, vol. 10, # 31, p. 5702 - 5714
  • 13
  • [ 18595-34-1 ]
  • [ 2212-75-1 ]
  • [ 2389-60-8 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1968, vol. 716, p. 175 - 185
  • 14
  • [ 16965-08-5 ]
  • [ 2212-75-1 ]
  • [ 2389-60-8 ]
Reference: [1] Journal of the Chemical Society [Section] C: Organic, 1967, p. 2632 - 2636
  • 15
  • [ 24424-99-5 ]
  • [ 657-27-2 ]
  • [ 501-53-1 ]
  • [ 2389-60-8 ]
Reference: [1] New Journal of Chemistry, 2018, vol. 42, # 4, p. 2450 - 2458
  • 16
  • [ 2389-60-8 ]
  • [ 2418-95-3 ]
Reference: [1] Synthetic Communications, 1981, vol. 11, # 4, p. 303 - 314
[2] Tetrahedron Letters, 2003, vol. 44, # 27, p. 4981 - 4984
[3] Organic and Biomolecular Chemistry, 2011, vol. 9, # 8, p. 2597 - 2601
[4] Chemische Berichte, 1972, vol. 105, # 2, p. 740 - 742
[5] Journal of the American Chemical Society, 1965, vol. 87, p. 99 - 104
[6] Chemical and Pharmaceutical Bulletin, 1981, vol. 29, # 9, p. 2592 - 2597
[7] Journal of Medicinal Chemistry, 2007, vol. 50, # 3, p. 550 - 565
  • 17
  • [ 100-02-7 ]
  • [ 2389-60-8 ]
  • [ 2212-69-3 ]
Reference: [1] Helvetica Chimica Acta, 1963, vol. 46, p. 1637 - 1669
[2] Chemical and Pharmaceutical Bulletin, 1981, vol. 29, # 9, p. 2592 - 2597
[3] Chemische Berichte, 1964, vol. 97, p. 1819 - 1828
[4] Justus Liebigs Annalen der Chemie, 1964, vol. 674, p. 218 - 225
[5] Journal of Organic Chemistry, 2003, vol. 68, # 4, p. 1314 - 1318
  • 18
  • [ 2389-60-8 ]
  • [ 34622-39-4 ]
Reference: [1] Journal of the American Chemical Society, 1982, vol. 104, # 16, p. 4446 - 4450
  • 19
  • [ 2389-60-8 ]
  • [ 101-83-7 ]
  • [ 2212-76-2 ]
Reference: [1] Patent: WO2008/14811, 2008, A1, . Location in patent: Page/Page column 17-18
  • 20
  • [ 2389-60-8 ]
  • [ 13288-57-8 ]
Reference: [1] Recueil des Travaux Chimiques des Pays Bas, 1983, vol. 102, # 11, p. 469 - 474
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 2389-60-8 ]

Amino Acid Derivatives

Chemical Structure| 2212-76-2

[ 2212-76-2 ]

Z-Lys(Boc)-OH.DCHA

Similarity: 0.98

Chemical Structure| 3350-13-8

[ 3350-13-8 ]

Dicyclohexylamine (S)-2-(((benzyloxy)carbonyl)amino)-4-((tert-butoxycarbonyl)amino)butanoate

Similarity: 0.97

Chemical Structure| 101854-42-6

[ 101854-42-6 ]

Boc-D-Dab(Z)-OH.DCHA

Similarity: 0.97

Chemical Structure| 214852-61-6

[ 214852-61-6 ]

Dicyclohexylamine (R)-2-(((benzyloxy)carbonyl)amino)-4-((tert-butoxycarbonyl)amino)butanoate

Similarity: 0.97

Chemical Structure| 16947-89-0

[ 16947-89-0 ]

Dicyclohexylamine (S)-4-(((benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)butanoate

Similarity: 0.97